24/7 Market News Snapshot 16 January, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

January 16, 2025

DENVER, Colo., 16 January, 2025 (247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp (SLXN), a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers, is experiencing significant market momentum following a positive pre-market trading performance. Shares of SLXN surged by an impressive 26.92%, reaching $1.980, up from the previous close of $1.560, with a trading volume of 1.13 million shares. This surge reflects heightened investor interest and confidence in the company’s innovative approach to oncology.

In a strategic move to bolster its research capabilities, Silexion has announced a public offering of 3,703,703 ordinary shares alongside warrants, aiming to raise approximately $5.0 million before expenses. The shares have been priced at $1.35 each, with the accompanying warrants granting investors the option to purchase additional shares at the same price. These warrants will be immediately exercisable and valid for five years, with the closing date for this offering projected for January 17, 2025, pending customary closing conditions.

The net proceeds from this public offering are earmarked for advancing Silexion’s preclinical studies and other corporate purposes. This initiative underscores the company’s dedication to pioneering therapies targeting the prevalent oncogenic KRAS mutations, particularly in solid tumors. Silexion’s lead candidate, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer, while the firm is also progressing its next-generation siRNA candidate, SIL-204, aimed at addressing a wider array of KRAS mutations.

As Silexion Therapeutics positions itself at the forefront of therapeutic innovation, the latest developments signal a strong commitment to enhancing patient outcomes for those battling formidable KRAS-driven cancers. The current market activity and funding strategies highlight SLXN’s potential for further growth as it navigates the evolving biotech landscape.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.